Shanghai Allist Pharmaceuticals: The 5-Billion RMB Oncology Island

I. Introduction & Episode Roadmap

In the autumn of 2012, a Shanghai biotech that had spent eight years and most of its founder's construction fortune developing China's first homegrown anti-hypertensive drug did something that looked, at the time, like surrender. It sold the drug outright. Rather than licensing regional rights or structuring a co-promotion agreement, the company transferred the complete domestic rights package to a Shenzhen pharmaceutical manufacturer for a headline consideration of RMB 1.02 billion.¹ The molecule's inventor, a molecular geneticist recruited home from the US National Institutes of Health, had died of illness just as the regulatory approval materialized.² Allist held an approved drug, but had neither a commercial sales team to market it nor a scientific founder left to discover the next compound.

Fourteen years later, that same enterprise — 上海艾力斯医药科技股份有限公司 Shanghai Allist Pharmaceuticals (688578.SS) — reported RMB 5.187 billion in revenue for 2025, up 45.8% year over year, with net profit attributable to shareholders rising 53.1% to RMB 2.189 billion.³ In the first half of 2026, it posted RMB 3.32 billion in revenue and RMB 1.541 billion in net profit, reflecting year-over-year growth of 39.85% and 46.57%, respectively.⁴ Gross margin stood near 96.9%.⁵ Cash and financial assets totaled approximately RMB 6.75 billion against no meaningful interest-bearing debt.⁶ By August 19, 2026, public equity markets valued the business at RMB 52.4 billion.⁷

Almost all of that revenue traces back to a single pill.

甲磺酸伏美替尼 Furmonertinib mesylate, marketed domestically under the brand 艾弗沙 Aifusha, is a third-generation EGFR tyrosine kinase inhibitor prescribed for non-small cell lung cancer (非小细胞肺癌 NSCLC). In 2025, it generated RMB 5.12 billion of Allist's RMB 5.187 billion in total top line, or 98.7% of corporate revenue.³ In the first half of 2026, it contributed RMB 3.138 billion, remaining near 95% of total sales even after two other oncology treatments entered national reimbursement.⁸ Allist is not a diversified pharmaceutical conglomerate. It operates essentially around a single molecule, an in-house commercial team assembled to drive hospital adoption, and a corporate treasury expanded by its operating cash flows.

That concentration forms the central tension of the investment story. On one reading, Allist is an exceptional case study in Chinese biopharma: an independent company that discovered a genuinely differentiated small molecule, commercialized it without surrendering margins to distribution partners, and accumulated a substantial cash balance with international royalty optionality attached. On the other reading, it represents what domestic financial media describe as a 五十亿单品孤岛 — a five-billion-RMB single-product island — operating against a ticking countdown clock. Eight third-generation EGFR inhibitors have now secured approval in China.⁹ That competitive crowding extends well past the threshold where the 国家医疗保障局 National Healthcare Security Administration (NHSA) historically concludes bilateral price negotiations and transitions therapies into centralized Volume-Based Procurement (集中带量采购 VBP), a bidding regime that routinely cuts domestic drug prices by 70% or more in a single tender.

Both perspectives are grounded in verifiable records. The objective of the analysis that follows is to determine which elements of each thesis withstand operational and commercial evidence. The roadmap proceeds in sequence: first, the unconventional founding — a construction developer, an NIH-trained geneticist, and an early asset sale that capitalized the business without institutional venture dilution. Second, the underlying science, showing how furmonertinib's market share is supported by distinct chemical and pharmacological properties rather than promotional spending alone. Third, the commercial rollout, including an executive transition and a distribution dispute that resulted in a RMB 255 million arbitration claim. Fourth, the hospital battleground, where Allist ranks as the third-largest player by sales volume in a market whose baseline pricing it does not control. Fifth, the cross-border licensing agreement with ArriVent Biopharma, where a pivotal global Phase III readout has been delayed twice. Finally, an evaluation of capital allocation, research pipeline breadth, and strategic frameworks — including 7 Powers and Porter's Five Forces — to stress-test the company's long-term competitive durability.

The narrative begins with where that initial capital originated.

↑ Back to Top

II. The Unlikely Genesis: Real Estate Capital, NIH Genetics, and the Alisartan Windfall (2004–2012)

Zhangjiang, in Shanghai's Pudong district, was mostly farmland and half-poured concrete in 2004. The district now known as 张江药谷 Zhangjiang Pharma Valley began as a government initiative: build the business parks, grant the tax incentives, and wait for returning Chinese scientists to establish laboratories. Most early tenants were contract research organizations and multinational satellite facilities. Almost no domestic operator attempted to develop a novel chemical entity from scratch, because few private entities in China had the capital to finance a compound through regulatory approval.

杜锦豪 Du Jinhao possessed that capital. He was not a pharmaceutical executive. Originating from Qidong in Jiangsu province, Du operated a construction and real estate business in Shanghai, accumulating wealth during the rapid urbanization cycle of the late 1990s and early 2000s. In the early 2000s, he allocated a substantial portion of those proceeds into innovative drug development — an investment posture that appeared contrarian at the time. Commercial real estate in that era yielded rapid capital turnover; domestic novel drug development absorbed capital for a decade with a material probability of total loss.

The scientific foundation came from the other half of the partnership. 郭建辉 Dr. Guo Jianhui was a senior molecular geneticist at the US National Institutes of Health, among the early cohort of foreign-trained researchers who returned to China during that decade. Allist was established in March 2004 as a joint venture pairing industrial capital with returning academic talent: the real estate developer provided equity financing, while the geneticist directed molecular discovery.² That governance structure was uncommon for its era. Most peer companies established around the same time relied on state research grants, in-licensed foreign compounds, or manufactured generic active pharmaceutical ingredients to sustain research budgets. Allist operated without those funding mechanisms, answering directly to a single controlling shareholder.

That shareholder was, and remains, Du himself. The structure carried distinct trade-offs: it lacked institutional board oversight and external strategic reviews, yet provided stability across multi-year development horizons. A traditional venture-backed biotech absorbing eight years of operating losses without commercial revenue would routinely face down-round recapitalizations, investor-driven strategic pivots, or forced asset sales. Allist instead operated under a private founder determining capital deployment.

The venture's initial target was not oncology, but cardiovascular disease. In a country with an expanding hypertensive population, hypertension presented an immediate commercial market. Guo's research team engineered 阿利沙坦酯 Alisartan Isoproxil, an angiotensin II receptor blocker (ARB) designed to serve as China's first domestically discovered Category 1.1 anti-hypertensive therapy.¹⁰ Eight years of preclinical chemistry, toxicology, and clinical trials followed, funded entirely from Du's balance sheet. The drug received its New Drug Certificate from domestic regulators in 2012.¹⁰

Two decisive events then unfolded in rapid succession.

First, Guo passed away from illness just as the molecule secured formal regulatory approval, depriving Allist of its founding scientific director.¹¹ Second, commercial realities intervened. Marketing an anti-hypertensive drug in China required nationwide distribution to thousands of primary care institutions and community health centers, competing directly against generic losartan and valsartan priced at steep discounts. Such a launch demanded a commercial field force of several thousand representatives. Allist employed only several dozen staff. Du evaluated the capital expenditures required to establish that retail marketing infrastructure and concluded the company could not compete effectively at that scale.

In October 2012, Allist agreed to sell the complete domestic rights to Alisartan Isoproxil to 深圳信立泰药业 Shenzhen Salubris Pharmaceuticals (002294.SZ) for a headline consideration of RMB 1.02 billion, structured as an upfront cash payment and milestone disbursements.¹¹² For an unlisted, pre-revenue Chinese biotech in 2012, the valuation was unprecedented. Critically, the transaction was non-dilutive. No private equity syndicate took board seats, and no venture funds secured liquidation preferences. Du and his family maintained control, ultimately retaining 54.05% of corporate voting rights when Allist completed its public listing eight years later.¹³

Testing the capital-allocation claim

A common narrative in financial commentary frames this divestment as a masterclass in strategic non-dilutive funding. That thesis warrants scrutiny against the operational record.

Salubris acquired a highly productive commercial asset. Over the following decade, Salubris expanded Alisartan into a multi-billion-RMB franchise, using it as the primary pillar for its cardiovascular portfolio through 2026.¹⁴ Every yuan of operating cash flow generated by that scale accrued to Salubris rather than Allist. Furthermore, the sale did not immediately establish corporate self-sufficiency: from the 2012 transaction until furmonertinib's initial regulatory approval in March 2021, Allist operated for nine years without a commercial product, consuming cash reserves to fund clinical-stage research. The business continued to report substantial net losses leading into its public debut, posting a net loss attributable to shareholders of RMB 397.5 million in 2019.¹³

Evaluating whether the divestment reflected strategic discipline or forced liquidation depends on how the proceeds were deployed. The RMB 1.02 billion was neither distributed as private dividends nor dispersed across unrelated commercial ventures. Instead, the capital funded nearly a decade of medicinal chemistry that generated AST2818, the kinase inhibitor that eventually became furmonertinib. Retaining Alisartan would have forced Allist either to dilute equity substantially to build a primary care sales force or to surrender distribution margins to a co-promotion partner — diverting management focus and capital precisely as its oncology program required dedicated clinical investment. The corporate record supports the capital-allocation thesis, with an important qualification: the transaction represented an effective decision made under operational constraints by a founder recognizing his organization's commercial limits, rather than proof of a repeatable corporate development process. Whether that disciplined capital deployment remains repeatable is an empirical question to test against Allist's subsequent in-licensing deals between 2023 and 2026.

One additional detail qualifies the thesis that Allist developed entirely outside institutional capital markets. Prior to its initial public offering, the company opened its equity register to institutional pre-IPO rounds, listing in Shanghai in 2020 under regulatory standards tailored for pre-revenue research enterprises.¹¹³ The assertion that Allist never raised outside equity is technically incorrect; the verifiable distinction is that management retained voting control and avoided raising dilutive equity under conditions of financial distress.

Above all, the 2012 divestment provided the balance sheet flexibility to execute a focused corporate pivot. Du chose non-small cell lung cancer.

↑ Back to Top

III. The Targeted Oncology Bet: Discovering Furmonertinib (2012–2020)

Allist's decision to redirect its balance sheet entirely into a single lung cancer target capitalized on a genetic divergence that distinguishes China's oncology market from Western patient cohorts.

Lung cancer represents China's leading malignancy by both incidence and mortality, but the underlying tumor biology differs significantly by geography. Among East Asian patients with non-small cell lung cancer, roughly 40% to 50% harbor activating mutations in the epidermal growth factor receptor (EGFR) gene — predominantly exon 19 deletions and the L858R point substitution — compared with approximately 15% in Caucasian populations.¹⁵ The EGFR protein spans the cell surface, relaying signals that direct cellular division. When mutated, the receptor acts as a switch jammed permanently in the active state, driving uncontrolled tumor proliferation.

This biological divergence created a distinct commercial opportunity: China holds the world's largest concentration of EGFR-mutant lung cancer patients, treated by a relatively small, identifiable group of thoracic oncologists concentrated in urban Class 3A tertiary hospitals. It is one of the few oncology specialties where an in-house commercial team of several hundred representatives can plausibly reach the majority of the relevant prescribing base.

First-generation targeted therapies — gefitinib, erlotinib, and later Betta Pharmaceuticals' domestic entrant icotinib — delivered strong initial clinical responses, but disease progression typically followed within nine to twelve months. In roughly half of those cases, resistance arose from a secondary gatekeeper mutation, T790M, located in the ATP-binding pocket. By altering the binding pocket's geometry, the tumor effectively changed the shape of the molecular lock. AstraZeneca addressed this resistance mechanism first with osimertinib (泰瑞沙 Tagrisso), an irreversible third-generation inhibitor engineered to target both the initial sensitizing mutations and T790M while sparing the unmutated, or "wild-type," EGFR that healthy skin and gastrointestinal cells require.¹⁶

That selectivity profile governs the therapeutic index of the entire drug class. Every EGFR tyrosine kinase inhibitor navigates an inherent pharmacodynamic trade-off: suppressing the oncogenic mutant receptor sufficiently to halt tumor progression without shutting down wild-type EGFR in healthy epithelial tissues. Inhibiting wild-type receptors triggers dose-limiting adverse events, primarily severe cutaneous rash and diarrhea. In clinical practice, wild-type toxicity establishes an unyielding dose ceiling across the class.

Allist's medicinal chemists focused directly on that structural ceiling. The candidate they developed, AST2818, employs a trifluoroethoxy-pyridine scaffold with two commercially critical pharmacological properties.

First, the company engineered what it designates as a "double-active" profile. Both the parent molecule and its primary circulating metabolite, AST5902, potently inhibit mutant EGFR with high selectivity over the wild-type receptor. The drug's therapeutic activity in systemic circulation is therefore sustained by two distinct active entities, neither of which causes significant off-target wild-type toxicity.

Second, because wild-type inhibition remains low, the tolerability ceiling rises. While the standard clinical dose for third-generation EGFR inhibitors is 80 milligrams once daily, clinical trials evaluated furmonertinib at 160 milligrams and 240 milligrams without triggering dose-limiting toxicity. That additional dosing headroom is not merely an incremental pharmacological detail; it represents the structural key to addressing two difficult clinical settings: central nervous system metastases and EGFR exon 20 insertion mutations, both of which demand higher systemic drug exposure than standard dosing achieves.

Central nervous system involvement represents a major clinical hurdle. Between 25% and 40% of patients with advanced EGFR-mutant NSCLC develop brain metastases, an outcome associated with accelerated disease progression, severe neurological impairment, and elevated mortality. Because the blood-brain barrier excludes most large or polar molecules, an inhibitor that crosses that barrier and can be safely escalated to higher doses provides a demonstrable clinical advantage in the patient segment oncologists find most challenging to treat.

Pivotal evidence arrived through the FURLONG trial, a double-blind, randomized Phase III study conducted across 55 hospitals in mainland China comparing furmonertinib head-to-head against gefitinib as a first-line therapy. Independent review showed median progression-free survival of 20.8 months for furmonertinib compared to 11.1 months for gefitinib, representing a hazard ratio of 0.44, or a 56% reduction in the risk of disease progression or death.¹⁷ The primary clinical results were published in The Lancet Respiratory Medicine in 2022, followed by a companion patient-reported-outcomes analysis in The Lancet Regional Health – Western Pacific confirming that superior efficacy did not compromise tolerability over extended treatment durations.¹⁸

Two strategic realities about Allist's development path contextualize its scientific achievement.

First, this was fast-follower medicinal chemistry rather than first-in-class category creation. AstraZeneca discovered and validated the third-generation EGFR mechanism; Allist optimized within an established paradigm. This distinction is not a critique — substantial enterprise value across biopharma often accrues to subsequent entrants that remediate the limitations of a pioneer molecule — but it defines Allist's technical positioning accurately. The company did not discover that sparing wild-type EGFR overcame resistance; it identified a chemical scaffold that improved that selectivity ratio and designed a clinical development program around the dosing flexibility that the ratio unlocked.

Second, that pharmacological optimization targeted a specific commercial opening. Expanding a drug's therapeutic index is clinically meaningful only if it translates into treatable patient populations that the standard of care underserves. By enabling higher dosing, Allist pursued indications where the market leader faced efficacy limits — most notably central nervous system metastases, the complication patients and clinicians fear most. That positioning reflected a clear commercial strategy executed through medicinal chemistry.

The clinical program spanned nearly a decade. Allist advanced AST2818 through Phase I dose escalation, completed second-line registration trials in T790M-positive patients, and initiated the head-to-head first-line Phase III study. By selecting a first-generation comparator, gefitinib, rather than third-generation osimertinib, Allist followed standard regulatory design in China while maximizing the demonstrable progression-free survival benefit. As clinical trials expanded across dozens of hospital sites, the entire program was funded internally from the Alisartan proceeds, generating years of accumulated operating losses.

The listing

Allist took the company public on the Shanghai Stock Exchange's 科创板 STAR Market on December 2, 2020, timing the offering ahead of furmonertinib's initial regulatory approval. The company issued 90 million shares at RMB 22.73 per share, raising RMB 2.046 billion in gross proceeds.¹³ The transaction utilized the STAR Market's fifth listing standard, a specialized framework designed for pre-revenue biotechnology firms that waives historical earnings requirements. Allist qualified under these provisions, having generated zero commercial product revenue. On its first trading day, the stock opened at RMB 42 and closed at RMB 38.55, a 69.6% gain that valued the business at RMB 17.35 billion.¹³¹⁹

The initial public offering served a specific strategic function. It was not the primary capital infusion that financed furmonertinib's discovery and early development; the Alisartan transaction had already supplied those funds. Instead, it represented a liquidity and corporate currency event, capitalizing on Phase III clinical data and an imminent regulatory approval during a receptive market window for domestic biopharma listings. Yet while Allist had engineered a viable molecule, it possessed no proven organizational capacity to sell one. Commercializing furmonertinib required an executive with firsthand experience scaling an oncology sales network across China's hospital system.

↑ Back to Top

IV. Building the Commercial Engine: The "Oncology Queen" and the Management Test (2020–2023)

In March 2020, nine months before the initial public offering and a year before regulatory approval, Du Jinhao stepped aside as general manager and appointed 牟艳萍 Mu Yanping to the role.

The hire marked a deliberate shift toward multinational commercial standards. Mu had spent her career within global pharmaceutical firms — including GSK, AstraZeneca, and Johnson & Johnson — before running the oncology business unit at 默沙东 MSD China, where she directed the commercial rollout of 帕博利珠单抗 pembrolizumab (可瑞达 Keytruda) and other major cancer therapies.²⁰ Domestic industry media frequently referred to her as the "Oncology Queen." Allist compensated her at a level reflecting that pedigree: her annual compensation of RMB 5.95 million exceeded the combined pay of the company's three vice presidents. Notably, she held no equity in the business.²⁰

That lack of equity alignment proved consequential during subsequent executive turnover.

Mu's initial mandate was to build a specialized oncology commercial organization virtually from scratch within twelve months, competing against formidable incumbents. AstraZeneca held a three-year head start with osimertinib, while 翰森制药 Hansoh Pharma (3692.HK) had launched its own domestic third-generation inhibitor, 阿美替尼 aumolertinib (阿美乐 Ameile), in March 2020. Rather than pursuing broad retail reach, Allist adopted a focused channel strategy: targeting thoracic surgery, pulmonology, and medical oncology departments across top-tier 三甲医院 Class 3A tertiary hospitals, complemented by direct-to-patient (DTP) specialty pharmacies licensed to dispense high-value oral oncology therapies. By late 2022, the in-house commercial team numbered roughly 480 marketing personnel covering 30 provinces, reaching approximately 1,000 hospitals and 500 DTP pharmacies.²⁰ By the time Allist published its 2025 annual report, that marketing organization had expanded beyond 1,700 personnel.²¹

This rapid buildout complicates the common perception that Allist achieved national scale entirely on its own. Recognizing that a 480-person sales force could not adequately cover the country, management sought outside commercial support. In May 2022, Allist signed an exclusive promotion agreement with 江苏复星 Jiangsu Fosun, a subsidiary of 复星医药 Fosun Pharma. The contract granted Fosun exclusive commercial promotion rights for furmonertinib across designated hospitals in specific regional territories through December 31, 2026, extending Allist's effective institutional reach beyond 1,500 hospitals.²⁰²² This hybrid structure served as a pragmatic bridge while the internal sales organization matured.

In parallel, Allist navigated domestic regulatory and market access pathways with unusual speed. The 国家药品监督管理局 National Medical Products Administration (NMPA) approved furmonertinib in March 2021 as a second-line therapy for EGFR T790M-mutated NSCLC. Later that year, Allist successfully negotiated the drug onto the 国家医保目录 National Reimbursement Drug List (NRDL), with coverage taking effect on January 1, 2022. Regulatory approval for the broader first-line setting arrived in June 2022 based on the FURLONG data, followed by NRDL inclusion effective March 1, 2023.²³ The financial inflection was immediate: corporate revenue grew from RMB 530 million in 2021 to RMB 790 million in 2022, before surging to RMB 1.978 billion in 2023 once first-line reimbursement took effect.³²⁰

The mechanics of the NRDL fundamentally govern this commercial trajectory. Securing national reimbursement requires accepting steep, mandatory price reductions in exchange for broad public insurance coverage and formulary access. For Chinese patients prescribed third-generation EGFR inhibitors, out-of-pocket annual treatment costs dropped from several hundred thousand yuan to approximately RMB 20,000.²⁴ That structural shift compresses unit realized price while drastically expanding eligible patient volume, with both parameters set by a single state payor. Consequently, every subsequent top-line milestone in Allist's history represents volume expansion achieved within a price envelope determined through state negotiations.

The second-order consequence of reimbursement is more operational: once therapy costs are subsidized, the primary commercial constraint shifts from patient affordability to institutional availability. A patient can benefit from reimbursement only if their treating hospital has completed the administrative formulary review required to stock the medication in its pharmacy. In China, hospital listing is an institution-by-institution, department-by-department process that often takes months or years. For an oncology sales force, operational execution centers as much on administrative access — securing hospital formulary inclusion and ensuring product stocking — as on clinical detailing. This operational reality explains why Allist's management routinely attributes top-line growth to key-account formulary expansion ahead of clinical metrics, and why the company relied extensively on DTP specialty pharmacies, which bypass hospital pharmacy listing delays by dispensing reimbursed oral therapies directly to patients upon prescription.

This institutional dynamic reframes Allist's performance between 2021 and 2023. Commercial gains did not stem from displacing the market leader purely on clinical differentiation. Instead, Allist executed an aggressive market-access rollout during a critical two-year window when first-line reimbursement was novel and the domestic market was contested by only three approved third-generation therapies rather than eight. Every hospital formulary slot secured during this phase established an incumbent barrier that subsequent entrants would have to displace. The long-term durability of that access moat remains an open question, representing the central variable tested by increasing market competition and moderating growth rates.

The executive shock

On September 14, 2022 — thirty months into her tenure and in the midst of the pivotal first-line commercial rollout — Allist announced that Mu Yanping had resigned as general manager for personal reasons. She transitioned to a senior consultancy role, while Du Jinhao returned to the general manager post he had occupied from 2004 to 2020.²⁵²⁶

Market reaction was swift and skeptical. Domestic financial commentators invoked the so-called "18-month curse" — a pattern of multinational pharmaceutical veterans departing emerging Chinese biotechs shortly after arrival — raising immediate questions about whether Allist's commercial momentum resided in institutional processes or individual relationships.²⁶ Skeptics argued that the clinical key-opinion-leader network, hospital formulary connections, and sales force discipline had been built almost entirely by an executive who held no corporate equity and had departed just as the first-line market expansion began.

Evaluating that skepticism against subsequent financial performance produces a clear conclusion. Rather than stalling, commercial momentum accelerated: corporate revenue climbed 155% in 2023 to RMB 1.978 billion, followed by a 77% increase in 2024 to RMB 3.506 billion from furmonertinib alone, and reached RMB 5.12 billion in 2025, an increase of 46%.²⁷ Far from unraveling, the commercial organization expanded to more than three times its 2022 size. The operational record indicates that the commercial engine did not depend on a single key executive. Ongoing sales were anchored by furmonertinib's differentiated clinical data and, critically, the structural tailwind of first-line national reimbursement — an access milestone that institutionalized clinical prescribing habits across hospital networks.

However, two operational realities temper this commercial resilience.

First, Allist demonstrated limited commercial operating leverage during its scaling phase. Selling expenses did not decline as a percentage of revenue as the top line expanded: in 2025, selling expenses reached RMB 2.076 billion, representing 40.0% of corporate revenue and rising 46.9% year over year — outpacing overall revenue growth.²⁸ Commercial expansion was sustained through continuous capital deployment into marketing channels rather than expanding operational efficiency.

Second, Allist's external commercial partnership unraveled into litigation. On November 30, 2023, Allist notified Jiangsu Fosun that it was unilaterally terminating their exclusive commercial promotion agreement. Fosun contested the termination as lacking contractual justification and filed for arbitration with the Shanghai International Economic and Trade Arbitration Commission in June 2024. Fosun sought RMB 255.46 million in aggregate claims, comprising RMB 26.94 million in unpaid promotion fees, RMB 226.17 million in contract damages, the return of commercial deposits, and legal expenses.²²²⁹ The arbitral tribunal held its initial hearing in January 2025, and as disclosed in Allist's 2025 annual report, the dispute remained pending resolution.³⁰

That dispute represents a material governance signal. Terminating a five-year agreement two years in, once the therapy had secured first-line reimbursement and the internal sales force had scaled, reads very differently to an external partner than to an operator cutting promotion fees. While an adverse arbitral award would be financially absorbable against more than RMB 2 billion in annual net profit, the reputational impact among prospective corporate partners represents a more significant strategic variable, especially when evaluating Allist's broader pipeline in-licensing strategy.

By late 2023, Allist's commercial infrastructure was fully established. The central question facing the business was no longer whether the organization could market furmonertinib, but how effectively that commercial engine could defend its margins against an expanding slate of direct therapeutic competitors.

↑ Back to Top

V. Core Economics & The China EGFR Battleground

On the thoracic oncology ward of a Class 3A hospital in Guangzhou or Chengdu in 2026, a newly diagnosed patient tests positive for an EGFR exon 19 deletion. The treating physician faces a crowded clinical menu: eight approved third-generation inhibitors, at least four of them fully reimbursed under the national drug list, all delivering broadly comparable progression-free survival in registrational trials, and all costing the patient roughly the same out-of-pocket expense under prices established by the NHSA.⁹²⁴

This is the commercial landscape Allist now navigates: not a protected therapeutic monopoly, but an increasingly contested market distinguished at the margins by clinical sub-segmentation.

The category evolved rapidly. AstraZeneca established the class with osimertinib and remains the international standard of care. Hansoh Pharma's aumolertinib arrived in March 2020 as the first domestic challenger and established an early volume lead: Hansoh guided to approximately RMB 6 billion in aumolertinib sales for 2025 against an estimated peak of RMB 8 billion, after booking RMB 4.531 billion in the first half of 2025 alone.³¹ Allist launched furmonertinib twelve months later. In May 2023, 贝达药业 Betta Pharmaceuticals secured approval for 贝福替尼 befotertinib, followed by entrants from 倍而达药业 Beda Pharmaceuticals and additional domestic drugmakers, expanding the approved cohort to eight therapies by 2026.⁹³²

The most revealing metric is not headline corporate revenue, but institutional hospital-channel market share. In 2025 sample hospital procurement data, sales reached roughly RMB 5.46 billion for osimertinib, RMB 4.65 billion for aumolertinib, and RMB 3.06 billion for furmonertinib, placing Allist third.²⁷ The RMB 2.06 billion variance between Allist's hospital sales and its reported RMB 5.12 billion in total furmonertinib revenue reflects the direct-to-patient specialty pharmacy network, where the company established an outsized early presence. That divergence yields two structural takeaways: Allist assembled an effective retail-specialty distribution footprint that cushions hospital formulary delays, but in the core institutional hospital channel that ultimately anchors guideline-driven oncology prescribing, it remains the third-ranking entrant.

This dynamic conceals a broader strategic asymmetry. AstraZeneca is not contesting Chinese EGFR share with the existential focus that Allist and Hansoh bring to the market. AstraZeneca's China revenue grew 3% in 2025 to $6.62 billion, as the multinational steadily diversified across therapeutic areas to reduce reliance on any single domestic oncology franchise.⁵³ For AstraZeneca, Chinese EGFR reimbursement is simply one negotiation among dozens across a global portfolio. For Allist, that single negotiation dictates corporate profitability. While this concentration can advantage an agile domestic player in the short term — motivating an in-house commercial team to battle aggressively for individual hospital listings — it leaves the business vulnerable over the longer cycle, offering no balance-sheet buffer when central authorities reduce baseline reimbursement prices.

What the drug actually delivers

The clinical rationale for furmonertinib rests on three attributes beyond headline progression-free survival from the FURLONG trial.

Central nervous system activity represents the compound's primary clinical differentiator. In patients with baseline brain metastases, furmonertinib demonstrated central nervous system progression-free survival comparable to its systemic result — a visible distinction in clinical practice that Allist's management has credited for the compound's reputation among oncologists.³³

Tolerability forms the second pillar. Because the molecule spares wild-type EGFR, Grade 3 or higher treatment-related rash and diarrhea remain infrequent. In an oral oncology regimen often maintained for two years or longer, fewer debilitating side effects directly improve patient persistence, keeping patients on therapy longer and sustaining chronic prescription volumes.

The third element is indication expansion, which began yielding regulatory additions in 2026. On February 6, 2026, the NMPA approved furmonertinib for advanced or metastatic NSCLC harboring EGFR exon 20 insertion mutations in patients who have progressed on or are intolerant to platinum-based chemotherapy — a second-line indication, cleared at the 240-milligram dose, based on the FURMO-003 Phase II study that reported a 51.4% objective response rate at the ESMO 2025 congress.³⁴ The decision established furmonertinib as China's first approved oral tyrosine kinase inhibitor for this historically treatment-resistant mutation, validating the clinical utility of AST2818's broader therapeutic window. Regulatory momentum continued in January 2026, when the Center for Drug Evaluation granted breakthrough therapy designation for first-line treatment of EGFR PACC mutations, another atypical-mutation niche, with a Phase III investigational new drug clearance following in April 2026.⁴

Yet the list is notable for what it omits. The most commercially significant label-expansion opportunity in EGFR-mutant lung cancer is post-operative adjuvant therapy — treating early-stage patients following surgical resection. Adjuvant treatment both broadens the addressable patient pool and substantially lengthens treatment duration. Allist's pivotal adjuvant Phase III trial completed patient enrollment in the first half of 2024 and has not yet reported results.³⁵ Meanwhile, Hansoh's aumolertinib secured adjuvant approvals as its third and fourth indications across 2025 and 2026, and the 2026 CSCO指南 CSCO guidelines carry Level I adjuvant recommendations for osimertinib, aumolertinib, and icotinib — omitting furmonertinib entirely.³¹³⁶ On the category's primary remaining volume driver, Allist trails its principal rivals, a lag documented directly in national clinical practice guidelines.

The economics, and what they conceal

The underlying economics of an oral small-molecule therapy resemble enterprise software. Production costs for an oral small molecule remain minimal, with Allist posting a 2025 gross margin of 96.87%.⁵ Operating expenses below the gross profit line tell a different strategic story. Below the gross line, research and development investment reached RMB 540 million in 2025, an increase of 12% that lagged corporate revenue growth of 45.8%, reducing R&D intensity to approximately 10.4% of sales.²⁸ Selling expenses absorbed 40.0% of revenue, leaving RMB 2.189 billion in net profit, a 42.2% net margin, and RMB 6.75 billion in cash and liquid financial assets.³⁶

While these figures reflect formidable operating cash flow, they also describe an enterprise harvesting an established asset rather than aggressively reinvesting in molecular discovery. The primary signal from the 2025 income statement is that Allist expanded marketing expenditures more rapidly than laboratory research, during a period when its core earnings stream rested on a single molecule confronting seven direct commercial competitors.

Testing the moat: the monopsony problem

The claim to test is that furmonertinib's clinical differentiation constitutes a durable commercial moat producing enduring supernormal cash flow. The structural mechanism that threatens that cash flow is not therapeutic obsolescence, but monopsony buying power.

Pricing across China's third-generation EGFR market is governed by a single entity. Historically, the NHSA transitions a therapeutic class from bilateral NRDL negotiations into centralized Volume-Based Procurement once multiple bioequivalent or clinically interchangeable suppliers enter the market — typically four to five manufacturers. First-generation EGFR inhibitors navigated that transition between 2018 and 2019, absorbing price reductions between 75% and 85% that halted top-line revenue growth for established brand leaders almost immediately. Eight approved third-generation therapies places the current category well beyond that historical trigger point.

Three commercial indicators demonstrate that margin compression has already commenced, operating in advance of any formal VBP tender.

First, furmonertinib's top-line revenue growth has decelerated along a defined trajectory: from 234.75% in 2022 to 150.38% in 2023, 77.25% in 2024, and 46.04% in 2025.²⁷ While the law of large numbers explains part of that trajectory, expanding market competition accounts for the rest.

Second, sequential revenue momentum has plateaued. Furmonertinib generated RMB 2.76 billion in the second half of 2025 and RMB 1.498 billion in the first quarter of 2026 — an all-time quarterly high by management's accounting, but representing virtually flat sequential performance on an annualized run-rate basis.²⁷

Third, and most directly, management confirmed during an April 23, 2026 investor call that gross margin contracted in the first quarter of 2026 partly due to an administrative NRDL price adjustment for furmonertinib effective January 2026, alongside higher manufacturing costs for newly launched in-licensed products.³³ Price concessions are no longer a prospective regulatory risk; they are registered directly on Allist's 2026 financial statements.

The eleventh national VBP round, with 55 drug categories reaching patients beginning in February 2026, did not include third-generation EGFR inhibitors in its bidding scope.³⁷ Yet regulatory authorities added osimertinib to the 2026 edition of the National Essential Medicines List in July 2026, signaling a structural transition in how the state views the drug class: no longer a scarce, high-cost breakthrough commanding pricing leeway, but an established standard of care to be procured at lower baseline cost.³⁸

Evaluating the durable-moat thesis yields a tempered conclusion. Furmonertinib possesses documented, clinician-recognized differentiation in treating brain metastases and refractory atypical mutations, supporting both hospital market share and patient persistence. But that pharmacological profile does not confer pricing power. In a monopsony reimbursement framework, the state resets realized prices on its own timetable, leaving the manufacturer to absorb margin degradation. The decisive commercial test over coming quarters is whether patient volume expansion across newly cleared indications can outpace mandatory price reductions — a dynamic visible in sequential revenue trends rather than lagging annual comparisons.

If domestic realized pricing remains governed by a state payor, the natural avenue for unconstrained commercial returns lies outside China.

↑ Back to Top

VI. The Overseas Optionality: ArriVent and the Global Exon 20 Wedge

In mid-2021, with furmonertinib three months into its domestic launch and corporate revenue still below RMB 1 billion for the year, Allist opted against retaining direct control of international development.

On June 30, 2021, Allist out-licensed exclusive rights to furmonertinib for all territories outside mainland China, Hong Kong, Macau, and Taiwan to ArriVent Biopharma, a US-based venture established specifically to develop the compound.³⁹ The transaction comprised a $40 million upfront cash payment, up to $765 million in potential development and commercial milestones, tiered royalties on net sales, and an equity stake in ArriVent itself.³⁹[^40]

The transaction structure addressed a clear operational constraint: Allist possessed no US regulatory infrastructure, no Western clinical development network, and limited appetite to finance either. Rather than licensing the molecule to a diversified multinational pharmaceutical firm where it risked deprioritization within a broader oncology pipeline, Allist partnered with a specialized development vehicle whose executive incentives aligned directly with advancing this single asset. ArriVent was formed by life-sciences venture investors and led by Dr. Bing Yao, who had previously co-founded and sold Viela Bio. When ArriVent completed its initial public offering on Nasdaq (AVBP) in January 2024, it established a liquid public valuation for Allist's equity position.[^56]

That structure differed markedly from the strategic alternatives available in 2021. Allist could have retained global rights to conduct clinical trials independently — the capital-intensive model pursued by 百济神州 BeiGene, requiring hundreds of millions of dollars in annual clinical expenditures and extensive multinational institution-building that an enterprise with sub-billion-RMB revenue could not have sustained without heavy equity dilution. Alternatively, it could have divested global rights to a multinational pharmaceutical firm for a larger upfront payment, accepting the risk that internal corporate realignments might sideline the program. The venture vehicle offered an intermediate path: externalizing development costs and operational execution while preserving commercial upside through equity appreciation and recurring royalties. Yet while the transaction architecture was pragmatic, its ultimate commercial payoff remains unproven five years after execution.

That public valuation has also illustrated the volatility inherent in early-stage biotechnology holdings. Allist accounts for its ArriVent equity as an investment in equity instruments designated at fair value through other comprehensive income, insulating its headline net profit from market fluctuations. In 2025, the fair value of that equity stake declined, an adjustment reflected in the movement in associated deferred tax liabilities disclosed in Allist's 2025 annual report.³⁰ Rather than expanding corporate value, the equity component of that overseas optionality has experienced net markdowns.

The clinical wedge

The commercial strategy behind the ArriVent partnership does not center on challenging osimertinib directly in frontline Western markets, where AstraZeneca has maintained an entrenched standard of care for nearly a decade. Instead, the program focuses on a defined clinical niche where established therapies provide limited benefit.

EGFR exon 20 insertion mutations represent a distinct subset of non-small cell lung cancer where standard third-generation inhibitors administered at conventional 80-milligram doses show minimal clinical activity. The insertion of extra amino acids alters the spatial configuration of the ATP-binding pocket, preventing the inhibitor from docking effectively — in biochemical terms, modifying the lock so the standard key cannot turn. Historically, the clinical default was conventional platinum-based chemotherapy. More recently, Johnson & Johnson established a targeted presence with Rybrevant (amivantamab), an EGFR/MET bispecific antibody approved in combination with chemotherapy following the PAPILLON trial.

Furmonertinib's wider therapeutic window provides the pharmacological rationale for entering this niche. At escalated dosages of 160 milligrams or 240 milligrams, systemic drug concentration reaches levels sufficient to overcome the altered binding geometry, while its selectivity over wild-type EGFR keeps treatment-related toxicities manageable. On the back of preliminary clinical activity, the US Food and Drug Administration granted furmonertinib Breakthrough Therapy designation for first-line EGFR exon 20 insertion NSCLC. ArriVent subsequently initiated FURVENT, a pivotal, global three-arm Phase III trial evaluating furmonertinib monotherapy at 160 milligrams and 240 milligrams against standard platinum-pemetrexed chemotherapy in previously untreated patients with advanced non-squamous disease. Patient enrollment completed in the first quarter of 2025 with 398 participants across clinical sites in the United States, Europe, Japan, and China, tracking progression-free survival by blinded independent central review as its primary endpoint.[^41] In parallel, ArriVent launched a second Phase III study, designated ALPACCA, evaluating the compound against PACC mutations, where the 240-milligram dose had demonstrated a 16-month median progression-free survival and a 68% confirmed objective response rate by central review in the earlier FURTHER trial.⁴⁰

Testing the global royalty claim

The central thesis advanced by market bulls is that ArriVent will transform furmonertinib into a high-margin global royalty stream, mirroring the commercial trajectory executed by 百济神州 BeiGene with its BTK inhibitor 泽布替尼 zanubrutinib (Brukinsa), which successfully transitioned from domestic discovery into an international commercial standard. Evaluating that claim against the operational record highlights three structural constraints.

The first constraint is regulatory. In February 2022, the FDA's Oncologic Drugs Advisory Committee voted against the approval of 信达生物 Innovent Biologics and Eli Lilly's PD-1 inhibitor 信迪利单抗 sintilimab based on the China-only ORIENT-11 trial, establishing an unambiguous policy precedent: domestic Chinese clinical datasets alone cannot support US regulatory approval without multiregional clinical trial data reflecting US population demographics. That decision mandated that the FURVENT trial be conducted as an extensive, multiregional trial spanning North American and European centers. While ArriVent absorbed those substantial clinical expenses — shielding Allist's income statement from operational burn — the multiregional requirement significantly prolonged the clinical development timeline.

The second constraint is the clinical timeline itself, which represents the primary empirical benchmark testing promotional expectations against clinical execution. In July 2025, ArriVent projected topline FURVENT data in early 2026.[^41] By May 2026, company guidance shifted to mid-2026. During an investor conference call on April 23, 2026, Allist management indicated that the trial would accumulate the necessary progression events around mid-year, anticipating presentation at the World Conference on Lung Cancer and forecasting regulatory approvals across the United States, European Union, and Japan in 2027 or later.³³ By ArriVent's second-quarter 2026 financial report, that guidance had slipped again to the second half of 2026.⁴⁰ In oncology drug development, timeline extensions in event-driven clinical trials are not uncommon, as progression endpoints naturally defer when patients experience durable disease control. Nonetheless, this pattern marked three successive reporting periods in which the primary catalyst of Allist's international thesis was postponed, and as of September 2026, the trial has yet to disclose topline results.

The third constraint is commercial positioning. Even under an optimistic clinical scenario where FURVENT meets its endpoints, furmonertinib would enter a US market where Johnson & Johnson already possesses an entrenched commercial franchise through Rybrevant's established hospital infusion footprint and specialized field force. Although ArriVent appointed a chief commercial officer to build domestic launch capabilities, its financial resources remain constrained relative to multinational competitors. ArriVent held $373.1 million in cash, cash equivalents, and marketable securities as of June 30, 2026, against a net loss of $93.2 million for the first six months of the year.³³⁴⁰ While that balance sheet provides operational runway into 2028, it leaves little flexibility to match the commercial detailing expenditure of a global pharmaceutical incumbent.

Competitive developments also challenge the perception that Allist is pioneering the international expansion of China's third-generation EGFR class. Hansoh Pharma secured that regulatory milestone first: aumolertinib received marketing authorization from the UK Medicines and Healthcare products Regulatory Agency (MHRA) in June 2025, marking the first Western regulatory clearance for a Chinese-developed EGFR tyrosine kinase inhibitor.³¹ Hansoh subsequently capitalized on that clearance by executing an international out-licensing agreement exceeding $1 billion in total milestone potential in December 2025.⁴¹

The operational evidence indicates that while Allist's international option remains active, its commercial realization remains unresolved, with execution requirements intensifying over time. Pharmacological activity in exon 20 insertions is supported by early clinical data, but translating that chemistry into high-margin royalty cash flows requires clearing three distinct hurdles: delivering statistically significant Phase III efficacy in the FURVENT trial, securing FDA approval no earlier than 2027, and successfully commercializing against an entrenched standard of care. To date, Allist has recorded zero commercial revenue outside China, while the equity asset marking that overseas optionality has undergone fair-value impairments. The singular catalyst determining the viability of that international thesis remains the forthcoming FURVENT readout.

While that regulatory clock ticks in Western markets, the more immediate strategic question centers on capital allocation at home: how Allist is deploying the substantial cash reserves accumulated from its domestic commercial franchise.

↑ Back to Top

VII. Capital Deployment & The Pipeline: Breaking the "Single-Product Island"

By the end of 2025, Allist held roughly RMB 6.75 billion in cash, deposits, and financial assets, against essentially no interest-bearing bank borrowing.⁶ For a company with an RMB 52 billion market capitalization, that represented more than an eighth of the enterprise held in corporate treasury reserves.⁷

Du Jinhao's response to capital deployment has remained consistent: acquire commercial-stage or near-commercial thoracic oncology assets that the existing field force can detail, without overpaying. The operational logic is straightforward: the marginal cost of adding a second or third therapy to a sales representative already detailing thoracic oncologists is minimal, leveraging the commercial network Allist established. Whether execution validates that platform strategy remains an open question.

The CStone deal. On November 8, 2023, Allist signed an exclusive commercialization and promotion agreement with 基石药业 CStone Pharmaceuticals (2616.HK) for 普拉替尼 pralsetinib (普吉华 Gavreto) in mainland China — a highly selective RET inhibitor approved for RET-fusion-positive NSCLC and RET-altered thyroid cancer.⁴² The transaction structure was revealing: CStone retained development, regulatory registration, and headline product sales, paying Allist a service fee for commercial promotion.⁴³ In this arrangement, Allist operates as a distribution contractor. That structure established a low-risk, low-return role for the sales force, and reported figures reflect those economics: pralsetinib contributed RMB 51.71 million in the first half of 2026.⁸

The Jacobio deal. On August 30, 2024, Allist secured exclusive Greater China rights to two assets from 加科思药业 Jacobio Pharmaceuticals (1167.HK): 戈来雷塞 glecirasib, a KRAS G12C inhibitor, and JAB-3312, an SHP2 inhibitor. Jacobio received approximately RMB 200 million near term — comprising an RMB 150 million upfront payment alongside roughly RMB 50 million in R&D cost reimbursements and other fees — with up to RMB 700 million in potential development and sales milestones, plus tiered double-digit royalties.⁴⁴⁴⁵ Glecirasib secured NMPA approval in May 2025 under the brand name 艾瑞凯, marking Jacobio's first commercial product, and entered national reimbursement effective January 2026.⁴⁶

This partnership offers a direct test of Allist's commercial platform thesis, though early commercial metrics reveal clear structural ceilings. Glecirasib recorded RMB 40.47 million in 2025 and RMB 130 million in the first half of 2026, with RMB 61.71 million in the first quarter alone — demonstrating sequential acceleration following reimbursement, while management described clinical uptake as running ahead of internal projections.⁸²⁷³³ Yet that growth must be weighed against epidemiological boundaries. KRAS G12C mutations occur in only 3% to 4% of Chinese non-small cell lung cancer cases, compared with roughly 13% in Western populations, with management confirming on an April 2026 conference call that observed clinical mutation rates match that 4% figure, offering only incremental upside from broader next-generation sequencing adoption.³³ RET fusions represent an even smaller patient fraction. Furthermore, 信达生物 Innovent Biologics and GenFleet Therapeutics brought their KRAS G12C inhibitor, 氟泽雷塞 fulzerasib, to the Chinese market ahead of Allist, while Eli Lilly's selpercatinib commands clinical mindshare in RET-driven tumors.

In short, these in-licensed therapies represent second-to-market entrants in small epidemiological niches. In the first half of 2026, glecirasib and pralsetinib together contributed approximately 5% of corporate revenue.⁸ While they enhance sales representative productivity across hospital wards, they cannot offset or replace an RMB 5 billion core franchise.

The ADC pivot. In August 2026, Allist shifted strategic direction in its most notable capital deployment to date. The company in-licensed Greater China rights to AST12608/ARR-002 — a potentially first-in-class MUC16/NaPi2b dual-target tetravalent antibody-drug conjugate (ADC) — from ArriVent for up to $80.6 million in upfront and milestone payments plus tiered revenue sharing, with ArriVent retaining commercial rights across all other global territories.⁴⁷⁴⁸ The initial target indications are ovarian and endometrial cancer.

Two operational realities define the transaction. First, the counterparty is ArriVent — the same partner to which Allist out-licensed furmonertinib's overseas rights, now in-licensing an asset back to Shanghai. This dynamic represents either an efficient collaboration between aligned partners or a transaction between entities with overlapping financial interests; Allist sits on both sides of a commercial relationship that it also holds as an equity investment on its balance sheet. How this arrangement is accounted for will become clear in the related-party disclosures of the 2026 annual report. Second, gynecological oncology operates in distinct clinical channels from thoracic oncology. The 1,700-person commercial field force detailing pulmonologists and thoracic surgeons cannot immediately cross over to market an ovarian cancer therapy. Whatever commercial synergies supported Allist's platform thesis, this transaction falls outside them.

A consistent pattern connects all three transactions. Allist has repeatedly acquired commercial or late-stage regional rights at modest upfront capital commitments — RMB 150 million to Jacobio, an undisclosed service-fee arrangement with CStone, and $80.6 million in total potential consideration to ArriVent — rather than financing large-scale clinical programs. That approach preserves capital and limits downside risk. However, it also reflects an organization acquiring incremental products to feed its sales network rather than securing a foundation for future corporate growth, explaining why cash reserves continue to accumulate despite completing three transactions in three years. None of the acquired assets carries the commercial scale to meaningfully alter the company's revenue profile, primarily because management has been unwilling to commit the capital required to acquire high-conviction assets.

In-house discovery. Allist's internal discovery pipeline remains in early clinical phases. AST2169, a selective KRAS G12D inhibitor administered as a liposomal injection, secured IND clearance in March 2024 and was conducting Phase I clinical trials by May 2025, targeting a mutation found in roughly 30% of pancreatic cancers, 12% of colorectal malignancies, and 4% of NSCLC.⁴⁹ A fourth-generation EGFR candidate targeting C797S triple-mutant resistance has cleared clinical entry.⁵⁰ Additionally, two proprietary ADC programs are advancing through chemistry, manufacturing, and controls development, with the first IND filing targeted for the third quarter of 2026 and the second planned for the first quarter of 2027.³³

Testing the diversification claim

The core investment thesis holds that external business development is resolving Allist's single-product concentration. Financial evidence does not support that view.

The operational record shows that three in-licensing transactions over three years generated, in aggregate, approximately 5% of total revenue in the first half of 2026. Meanwhile, research and development spending has moderated: R&D intensity declined throughout 2025, and in the first half of 2026, research expenditures dropped 14.3% year over year to RMB 254 million, representing just 7.66% of revenue, while selling expenses rose 31.07% to RMB 1.241 billion.⁸ For an oncology business confronting administrative price cuts on its core franchise, prioritizing marketing outlays over internal research constitutes a strategic choice to harvest an established asset.

The counterweight to this critique is that management has avoided capital-destructive missteps. Du Jinhao has avoided speculative mega-acquisitions, debt-financed transactions, or unrelated diversifications into healthcare facilities or medical devices. Furthermore, the company has begun returning excess capital to shareholders: distributing RMB 450 million for 2025, or approximately 20.6% of attributable net profit, followed by an interim dividend of RMB 6.00 per 10 shares in the first half of 2026 totaling roughly RMB 270 million, of which approximately RMB 86.86 million accrued to the controlling shareholder.⁷²⁸ The narrative that Allist merely hoards cash without shareholder distributions is no longer consistent with corporate filings.

The calibrated conclusion is that Allist's capital deployment has been disciplined and non-destructive, but has not yet created significant enterprise value. The in-licensed assets are commercially viable and modestly priced, but structurally limited in scale. The empirical benchmark that would challenge this cautious assessment is combined non-furmonertinib revenue: if annualized sales from glecirasib, pralsetinib, and subsequent assets surpass RMB 500 million, the commercial platform thesis will have operational backing. Below that threshold, secondary assets remain minor contributors against the single-product core — the central tension dominating ongoing investor dialogue.

↑ Back to Top

VIII. Primary Sources & Analyst Interrogations: The Conference Call Record

Chinese A-share companies do not hold quarterly earnings calls in the conventional Western format. Instead, they conduct 投资者关系活动 — structured investor relations exchanges, formally minuted and filed with the Shanghai Stock Exchange, where sell-side analysts from major domestic brokerages submit targeted questions and executive management responds on the official record. For Allist, these filings, alongside annual and interim reports, offer the closest available approximation of a live transcript capturing the ongoing debate between executive leadership and public shareholders.⁵¹

Read across the 2025 and 2026 sessions, three primary tensions recur.

The peak sales ceiling. Management's consistent framing is that furmonertinib retains substantial commercial runway, propelled by indication expansion rather than market-share gains. At the April 23, 2026 session, the company attributed strong first-quarter performance to six operational factors, in this explicit order: clinical recognition of the drug's central nervous system efficacy, expanded hospital access driven by key-account teams, deeper penetration into lower-tier municipal markets, maturation of the internal sales organization, the February 2026 second-line exon 20 insertion approval, and post-reimbursement volume uptake for glecirasib and pralsetinib.³³ When analysts pressed for full-year revenue guidance, executive leadership pointed to "sustained growth momentum" rather than committing to a specific financial figure.

That response reveals critical operational dynamics. Three of the six identified drivers — key-account hospital expansion, lower-tier market penetration, and sales force maturation — reflect commercial distribution effort rather than clinical differentiation. They represent the operational levers an enterprise pulls when expansion requires working harder within a category that is no longer expanding spontaneously. To its credit, management has maintained this characterization consistently across investor exchanges, avoiding claims of market-share gains it has not demonstrated.

Volume-based procurement. This is where corporate messaging and analyst interrogation diverge most sharply. Management's position, reiterated across sessions, is that clinical differentiation — robust brain-metastasis penetration, atypical-mutation label expansions, and preferential positioning in CSCO guidelines — insulates furmonertinib from therapeutic commoditization. Yet when pushed to quantify how the income statement would absorb a mandatory VBP tender, leadership has consistently declined to model the scenario, offering general reassurances that expanding patient volume will compensate for price erosion.

Management's reluctance to model that downside is understandable, but analysts persist because the company's own financial disclosures bound that reassurance. On the same April 2026 call at which leadership emphasized clinical differentiation, management attributed a first-quarter gross margin contraction directly to an administrative NRDL price adjustment on furmonertinib effective January 2026.³³ Pharmacological differentiation did not shield the franchise from an administrative price reduction. Furthermore, when addressing future gross margins, management guided to stability — projecting "comparable levels" for the full year — through supply-chain optimization on in-licensed therapies rather than through baseline pricing power.³³ That posture reflects an enterprise managing manufacturing costs because it cannot control price.

Capital deployment. A recurring challenge from domestic analysts centers on why an enterprise holding RMB 6.75 billion in liquid treasury reserves alongside an approaching domestic pricing cliff is not deploying capital more aggressively into late-stage clinical assets. Management's stated rationale is that it maintains this liquidity buffer to finance ongoing multinational and domestic Phase III programs — spanning adjuvant therapy, PACC mutations, frontline exon 20 insertions, and proprietary combination regimens — while waiting for broader biopharma market valuations to rationalize. In evaluating combination regimens, Allist has emphasized a disciplined sequence: establishing baseline safety and monotherapy efficacy before pursuing formal combination trials with furmonertinib or glecirasib.³³

Two distinct realities coexist here. On one hand, capital allocation has remained consistent with stated corporate policy across multiple operating cycles — passing the fundamental test of managerial consistency. On the other hand, that conservative posture coincided with research and development spending rising just 12% in 2025 while selling expenses climbed nearly 47%, an allocation pattern that sits uneasily alongside claims of aggressively funding multi-indication Phase III trials.²⁸

A fourth theme emerges from the transcripts where management offered its most concrete operational disclosures. When questioned regarding the pivotal adjuvant program, leadership moved beyond generic confidence to detail a specific trial design: arguing that its registrational studies evaluate a broader risk cohort — encompassing stage IA2-plus patients — than competing adjuvant trials, while enrolling patients with both classical and non-classical EGFR mutations.³³ That claim represents a verifiable, falsifiable trial design distinction rather than promotional rhetoric. Yet it also implicitly concedes the competitive reality: Allist is pursuing differentiation through eligible patient breadth precisely because it surrendered first-mover advantage to rival therapies already entrenched in clinical guidelines.

On the international development program, management's disclosures have been similarly detailed, though fluid regarding execution milestones. The April 2026 guidance — projecting that the FURVENT trial would reach its required progression event count around mid-year, with clinical data presented at a major medical congress and regulatory filings in the United States, European Union, and Japan targeted for 2027 or later — established a verifiable operational benchmark.³³ Notably, this projection was more conservative than ArriVent's own contemporaneous public guidance, creating an unusual divergence where the domestic licensor communicated a more deliberate schedule to its shareholders than its foreign partner presented to Western investors.

A final, revealing record from corporate disclosures centers on insider capital movements. Allist's employee shareholding platforms, through which more than 100 core personnel acquired equity at approximately RMB 9.82 to RMB 9.92 per share during pre-commercial, loss-making years, disclosed plans to divest up to 13.5 million shares — roughly 3% of total corporate share capital — beginning September 1, 2025, representing maximum gross proceeds near RMB 1.2 billion and an average realization of roughly RMB 10 million per participant.⁵² Employee equity incentives exist to be monetized, and these awards originated long before public listing. Nevertheless, a coordinated 3% divestment by the personnel closest to day-to-day commercial operations — initiated just as top-line revenue growth moderates and mandatory price adjustments begin — provides an essential empirical counterweight to executive optimism on investor calls.

↑ Back to Top

IX. Strategic Frameworks: 7 Powers & Porter's Five Forces

Stripping the corporate narrative away reveals which structural advantages genuinely endure.

Cornered Resource — real but narrow. Furmonertinib's composition-of-matter patent and its distinct pharmacology — the dual parent-metabolite activity, low wild-type EGFR inhibition permitting 160-milligram and 240-milligram dosing, and robust central nervous system penetration — constitute a genuine cornered resource. No competitor can copy the molecule during its patent life, and that dosing headroom unlocked the exon 20 insertion and PACC labels that no other approved domestic third-generation inhibitor currently holds. The limitation is that a cornered resource protects the chemical entity, not its unit price. Seven other pharmaceutical manufacturers own their own proprietary compounds directed at the exact same receptor, and the single state payor treats them as therapeutic substitutes.

Scale Economies and Process Power — moderate, and partly rented. A specialized commercial organization of more than 1,700 personnel embedded across Class 3A tertiary hospitals and DTP specialty pharmacies represents a tangible distribution asset, providing low marginal delivery costs for detailing additional thoracic oncology therapies.²¹ Glecirasib's post-reimbursement volume acceleration offers initial evidence that this cross-selling logic functions in practice.⁸ Yet three operational realities qualify that advantage: the sales force absorbed 40.0% of corporate revenue in 2025, with selling expenses expanding faster than the top line;²⁸ historical hospital reach was subsidized by an exclusive regional partnership with Jiangsu Fosun that Allist unilaterally terminated and is now contesting in arbitration;²² and the company's newest in-licensed asset, a gynecological oncology ADC, cannot leverage this thoracic commercial network at all.⁴⁷

Switching Costs — moderate, and asymmetric. An oncologist will not switch a patient whose tumor is stably controlled on furmonertinib over to an alternative kinase inhibitor. That clinical inertia protects the existing installed base, sustaining multi-year revenue duration for enrolled patients. However, switching costs provide zero protection in newly diagnosed, treatment-naive patients — the entire source of category volume growth — where treating clinicians select among eight clinically viable options delivering broadly comparable outcomes at state-standardized out-of-pocket costs.

Counter-Positioning — absent. Allist operates the identical commercial playbook as AstraZeneca and Hansoh Pharma: discover or in-license a targeted small molecule, secure national reimbursement, and deploy a specialized sales force to detail hospital oncologists. There is no business-model asymmetry that an incumbent cannot adopt, nor any disruptive mechanism that copying would damage an incumbent's core revenue. Counter-positioning is entirely absent.

Network Effects and Branding — absent and negligible. One patient's daily prescription generates zero utility or network value for the next. Brand equity in domestic prescription pharmaceuticals functions primarily as physician familiarity and institutional habit, which competitors systematically match through comparable academic promotion and medical detailing budgets.

Evaluated through Porter's Five Forces, the structural headwinds become more pronounced.

Buyer Power is extreme and forms the central economic reality of the enterprise. A single monopsony buyer — the National Healthcare Security Administration — dictates baseline pricing across roughly 95% of Allist's corporate revenue through periodic NRDL negotiations and, prospectively, centralized Volume-Based Procurement. The administrative price adjustment implemented in January 2026 provided direct confirmation of this pricing ceiling.³³ Pharmacological differentiation may drive physician preference, but it does not alter who controls the reimbursement tariff.

Rivalry among existing competitors is intense. Eight third-generation EGFR inhibitors have secured regulatory approval in China, with at least four covered under national reimbursement. In the core institutional hospital channel, both AstraZeneca and Hansoh generate substantially higher sales volumes than Allist, while Hansoh commands a decisive first-mover lead on adjuvant label expansion and Western regulatory clearance.²⁷³¹

Threat of Substitutes is high across a five- to seven-year horizon. Next-generation treatment paradigms threaten to displace oral EGFR monotherapy entirely. Johnson & Johnson's amivantamab-plus-lazertinib combination demonstrated superior progression-free survival over osimertinib monotherapy in the frontline MARIPOSA trial, while HER3- and TROP2-directed antibody-drug conjugates are advancing rapidly in global clinical pipelines. If chemotherapy-free bispecific combinations or frontline ADCs establish themselves as the new standard of care, the entire third-generation oral tyrosine kinase inhibitor class risks relegation to maintenance or second-line salvage settings. Allist's hedge against this modality shift — two internal preclinical ADC candidates and an in-licensed early-stage asset — remains at the investigational new drug clearance stage or earlier.³³

Bargaining Power of Suppliers is low. Active pharmaceutical ingredient synthesis and oral solid dose manufacturing are mature, highly commoditized processes. Allist operates in-house manufacturing facilities alongside domestic contract development and manufacturing organizations, with internal production transfers for newly in-licensed assets underway to rein in unit costs.³³

Threat of New Entrants is low within third-generation EGFR but rising across adjacent modalities. Steep reimbursement price reductions have effectively closed the commercial window for additional me-too entrants targeting the same molecular profile. Instead, competitive entry has migrated upstream to fourth-generation inhibitors targeting allosteric resistance mutations and novel modalities designed to bypass the kinase target altogether, where multiple domestic biopharmaceutical developers have already advanced candidates into clinical trials.³²

A constructive stress test for this business is to isolate the enterprise from its flagship molecule. Stripped of furmonertinib, Allist consists of a 1,700-person specialized oncology commercial team, RMB 6.75 billion in corporate cash and liquid investments, a modest early-stage research laboratory, and regional distribution rights to two niche targeted therapies. That configuration describes a viable commercial-stage specialty pharmaceutical distributor, but it does not resemble a business commanding an equity valuation above RMB 50 billion. Nearly the entirety of the enterprise value represents the discounted cash flows of a single patent-protected chemical entity sold to a single monopsony buyer at a tariff that buyer determines.

The strategic synthesis is straightforward: Allist owns an exceptional asset operating inside an unfavorable industry structure. A strong product trapped in a weak industry is a fundamentally different investment proposition from an enduring franchise occupying an attractive market. That structural disconnect explains why market participants remain so sharply divided over the company's long-term terminal value.

↑ Back to Top

X. The Bear vs. Bull Investment Stress Test

The bull case rests on four distinct propositions, each supported by documented commercial or clinical milestones.

First, indication expansion extends the domestic revenue ceiling. The second-line label for exon 20 insertions is already approved and eligible for reimbursement; the frontline PACC indication carries breakthrough therapy designation and a cleared Phase III investigational new drug application; and the pivotal adjuvant Phase III trial completed enrollment in 2024 and awaits a data readout.⁴³⁴³⁵ Post-operative adjuvant therapy represents the primary volume catalyst: industry estimates project the Chinese EGFR adjuvant market could approach RMB 10 billion by 2030.²⁷ A positive clinical readout would expand Allist's addressable cohort from late-stage metastatic disease to early-stage patients maintained on continuous therapy across multi-year treatment cycles.

Second, the ArriVent partnership delivers overseas monetization. Statistically significant data from the FURVENT trial would unlock development milestones, generate tiered royalties on net sales across North America and Europe, and prompt a positive revaluation of Allist's equity stake — high-margin economics that accrue directly to the balance sheet without associated clinical development or marketing expenditures.

Third, the commercial platform demonstrates operating leverage. Glecirasib's sales acceleration following national reimbursement offers tangible operational evidence that the internal sales force functions as a scalable distribution asset rather than a fixed cost center, allowing subsequent in-licensed therapies to plug directly into the established hospital channel.⁸³³

Fourth, substantial balance sheet liquidity provides strategic optionality while supporting shareholder distributions. Maintaining roughly RMB 6.75 billion in liquid financial reserves during a broader biopharmaceutical funding contraction enables disciplined asset acquisitions at favorable valuations, even as the company has transitioned from pure cash accumulation to distributing recurring dividends.⁶⁷

The bear case, by contrast, rests on structural headwinds that find direct support across recent financial and operational filings.

First, domestic pricing mechanisms have already begun compressing margins. This price erosion is not a prospective 2027 risk: the January 2026 NRDL price concession narrowed gross margins in the first quarter of 2026, annual revenue growth has decelerated across four consecutive fiscal years, and sequential revenue from the second half of 2025 to the first quarter of 2026 remained virtually flat.²⁷³³ If the NHSA subjects the third-generation class to centralized Volume-Based Procurement, historical first-generation precedent suggests baseline price cuts exceeding 70%. In a crowded market where eight approved manufacturers contest the same pool of incident patients, prescription volume cannot plausibly expand threefold to offset that price compression.

Second, the therapeutic category risks clinical displacement from above. Frontline bispecific antibody combinations and next-generation antibody-drug conjugates are advancing toward first-line standard-of-care status. Allist's strategic counterweight — two proprietary preclinical ADC programs and an in-licensed candidate — remains at the investigational new drug filing stage or earlier.

Third, the long-term pipeline void remains unresolved. No internal successor compound has reached late-stage clinical trials; the in-licensed assets target small epidemiological niches representing roughly 3% to 4% and 1% to 2% of the non-small cell lung cancer population; and research and development spending has steadily contracted as a percentage of revenue, declining in absolute terms during the first half of 2026.⁸²⁷²⁸

Fourth, the overseas commercial optionality has experienced successive timeline delays and a balance-sheet impairment, with the pivotal FURVENT data readout deferred across three reporting intervals while Allist's equity stake in ArriVent has undergone net fair-value markdowns.³⁰[^41]⁴⁰

A subtler operational signal in the 2025 financial disclosures reinforces these structural concerns. Finished goods inventory for furmonertinib surged 125.08% year over year while production volume expanded 59.39% — both metrics significantly outpacing corporate sales growth of roughly 46%.²⁷ Benign explanations exist: building buffer stock ahead of the exon 20 insertion commercial rollout, rebalancing logistics between institutional hospital pharmacies and retail DTP channels, or preparing for the internal manufacturing transfer of newly licensed therapies. Yet a less favorable explanation is that channel distribution pipelines are absorbing volume faster than end-patient prescription demand is consuming it. This divergence between inventory accumulation and end-market absorption is an operational trend that typically clarifies over several reporting quarters, making it a critical leading indicator for analysts to track.

Governance considerations introduce an additional layer of scrutiny. Corporate disclosures detail an unresolved RMB 255 million arbitration proceeding stemming from the unilateral termination of a regional promotion agreement;²² a coordinated divestment plan by employee shareholding platforms encompassing up to 3% of corporate equity initiated just as revenue momentum moderates;⁵² a founder-controlled ownership structure retaining 54.05% of voting rights without external institutional checks on capital allocation;¹³ and an in-licensing transaction concluded with an overseas partner in which Allist holds an equity position.⁴⁷ While none of these factors is disqualifying on its own, together they delineate an enterprise where strategic governance rests almost entirely on the judgment of a single controlling shareholder.

The KPIs that matter. Three key performance indicators serve as the definitive benchmarks for tracking this investment thesis.

First, sequential furmonertinib revenue. The critical metric is not year-over-year percentage growth, which benefits from favorable prior-year comparisons, but sequential, quarter-over-quarter top-line revenue in absolute yuan. This single data series isolates the net effect of clinical volume expansion against administered reimbursement price reductions, capturing the core domestic dynamic in a single figure.

Second, NHSA regulatory policy regarding third-generation EGFR inhibitors. Specifically, whether regulatory authorities transition the drug class into a centralized VBP procurement catalog and what pricing formulas are applied during periodic NRDL renewals. This represents a discrete policy event capable of resetting the entire corporate revenue base, demanding ongoing regulatory monitoring rather than speculative financial modeling.

Third, topline clinical data from the FURVENT trial and subsequent regulatory submissions. The decisive benchmark is not the procedural continuation of the trial, but the disclosure of verified progression-free survival data and the subsequent acceptance of an FDA new drug application. Every element of the overseas expansion thesis remains downstream of this clinical readout.

Other operational developments — the adjuvant Phase III readout, early-stage ADC investigational new drug clearances, the pending commercial arbitration, and interim gross margin fluctuations — remain informative but secondary. If sequential domestic revenue expands while the drug class avoids centralized procurement and FURVENT delivers robust clinical efficacy, the bull thesis retains viability. If sequential domestic sales decelerate just as centralized procurement resets baseline pricing and the overseas readout falls short, no early-stage pipeline narrative can cushion the impact, given the absence of secondary revenue streams capable of absorbing the shortfall.

Finally, an analytical assessment must recognize the structural limits of forecasting state healthcare policy. The specific timing and pricing severity of any future VBP tender for third-generation EGFR tyrosine kinase inhibitors reflect state administrative discretion rather than quantifiable financial projections. The soundest analytical posture is to treat centralized procurement as an active operational variable with clear historical precedent — characterized by 75% to 85% price reductions during the first-generation tender — rather than as an improbable tail risk to be discounted simply because formal implementation has not yet occurred.

↑ Back to Top

XI. Epilogue & Playbook: Business & Investing Lessons

One reading of Allist's trajectory presents it as an unalloyed success story: a real estate developer and an NIH-trained geneticist partnered in Zhangjiang, spent eight years and a construction fortune developing a compound they were ultimately forced to divest, endured the loss of their scientific founder, and directed the entire proceeds into a single oncogene in China's deadliest malignancy. Fourteen years later, that focused bet produced a commercial franchise generating more than RMB 2 billion in annual net profit at 42% net margins with virtually no interest-bearing debt.

Three durable strategic lessons emerge from that record, cutting through standard corporate narratives.

The first centers on non-dilutive capital. Divesting Alisartan was not a masterclass in strategic foresight; it was a pragmatic sale forced by commercial limitations under difficult circumstances. What made the transaction consequential was the discipline that followed: management treated the proceeds as an endowment rather than corporate spending money, funding a decade of patient, undiluted chemistry on a single high-conviction program. The takeaway is not that early-stage biotechs should divest their initial assets. It is that the value of non-dilutive capital compounds only if leadership resists the temptation to disperse it across tangential ventures.

The second lesson concerns organizational focus. By concentrating exclusively on thoracic oncology, an enterprise of fewer than 2,000 personnel matched the hospital reach of multinational pharmaceutical conglomerates across a single patient segment. That commercial density represents Allist's most valuable operating asset. Yet focus functions as a constraint as much as an advantage. It explains why an in-licensed gynecological ADC sits awkwardly outside the clinical channels its field force navigates, and why the contentious split with Jiangsu Fosun generated operational friction. When an organization builds its entire commercial infrastructure around a single clinical department, expanding beyond those borders immediately exposes the limits of the model.

The third lesson defines the structural limits of incremental clinical differentiation. Furmonertinib proved superior to the first-generation inhibitors it superseded and established meaningful pharmacological separation on tolerability and dosing headroom within its own class. That differentiation was sufficient to construct a multi-billion-RMB franchise, but it could not preserve baseline pricing. In China's oncology market, refined chemistry can secure prescribing volume and treatment duration; it cannot confer pricing power. In a monopsony healthcare system, pricing power resides permanently with the state payor, which extends premium pricing only until sufficient therapeutic alternatives enter the market. Every domestic biopharmaceutical thesis eventually confronts that reality. The operators that endure do so by advancing a second commercial pillar before administrative authorities reprice the first.

That dynamic defines Allist's strategic crossroads in September 2026. The initial act was a verified commercial and operational success. The second act remains an open question: an adjuvant trial that has yet to report data, a pivotal global Phase III readout whose timeline has slipped across three reporting cycles, two niche in-licensed assets contributing just 5% of corporate revenue, early-stage ADC candidates entering the clinic, and a corporate treasury whose highest-return deployment remains unproven. Allist mastered what is often the most formidable challenge in biotechnology: discovering a differentiated molecule and establishing deep clinical adoption across top-tier hospitals. It has yet to demonstrate that it can replicate that feat — and in commercial biopharma, replication is what separates an enduring enterprise from a single-product island.

References

1. 艾力斯：16载潜心研发磨出两个创新药 — 中国证券网, 2020-12-02 ↩↩↩

2. 肺癌靶向药巨头，一年净赚6.44亿 — 新浪新闻 ↩↩

3. 艾力斯2025年财报透视：单品独撑52亿营收 后续接棒乏力 — 财联社, 2026-04-22 ↩↩↩↩

4. 艾力斯上半年净利润同比增长46.57% 拟每10股派6元 — 证券时报, 2026-08-19 ↩↩↩

5. 艾力斯（688578）2025年报简析 — 同花顺金融服务网 ↩↩

6. 财报快递｜艾力斯(688578)2025年度营收净利双增超45%，销售费用激增近五成，研发投入占比下滑 — 证券之星, 2026-04-24 ↩↩↩↩

7. 肿瘤药企艾力斯上半年净利同比增约47%，拟10派6元 — 每日经济新闻, 2026-08-19 ↩↩↩↩

8. 一款治疗肺癌药半年卖超30亿，支撑超9成营收！艾力斯或仍存单品依赖问题 — 网易, 2026-08 ↩↩↩↩↩↩↩↩

9. 艾力斯2025年财报透视：单品独撑52亿营收，后续接棒乏力 — 蓝鲸财经, 2026-04-22 ↩↩↩

10. 1.1类新药阿利沙坦酯获生产批件 — 中国医药创新促进会 ↩↩

11. 艾力斯"爆款神话"：靠一款肺癌药净赚10亿 — 36氪 ↩

12. Shenzhen Salubris Pharmaceuticals Acquisition of Alisartan Isoproxil Technology Transfer Agreement — Shenzhen Stock Exchange, 2012-10-18 ↩

13. 艾力斯科创板上市：市值173亿 去年亏损近4亿 — 新浪财经, 2020-12-02 ↩↩↩↩↩↩

14. 信立泰市值700亿，押注200亿美元潜力大单能否打开新空间？ — 新浪财经, 2026-04-10 ↩

15. Consensus on Application of Third-generation EGFR-TKI in EGFR Mutated NSCLC (2022 Version) — Chinese Journal of Lung Cancer / PMC ↩

16. 肺癌热门靶点EGFR-TKI：迭代"三代同堂"，造就百亿级潜力市场 — 摩熵医药 ↩

17. Furmonertinib (AST2818) versus gefitinib as first-line therapy for Chinese patients with locally advanced or metastatic EGFR mutation-positive non-small-cell lung cancer (FURLONG): a multicentre, double-blind, randomised phase 3 study — The Lancet Respiratory Medicine, 2022-11 ↩

18. Patient-reported outcomes for the phase 3 FURLONG study of furmonertinib versus gefitinib — The Lancet Regional Health – Western Pacific, 2024 ↩

19. 艾力斯上市！中1签赚8800元，收益率77.43% — 新浪财经, 2020-12-02 ↩

20. 艾力斯总经理"肿瘤女王"牟艳萍辞职，核心产品商业化生变 — 界面新闻, 2022-09-15 ↩↩↩↩↩

21. 上海艾力斯医药科技股份有限公司2025年年度报告摘要 — 上海证券交易所, 2026-04-22 ↩↩

22. 复星医药与艾力斯的"独家推广"纠纷升级：2.55亿仲裁索赔案引发关注 — 新浪财经, 2024-10-21 ↩↩↩↩

23. 艾力斯医药：突破性肺癌新药艾弗沙®纳入医保，四代EGFR候选分子获批临床 — 摩熵医药 ↩

24. 一、二、三代EGFR TKI最新医保价格 — 医药魔方 ByDrug ↩↩

25. 艾力斯总经理牟艳萍女士辞职 — 医药魔方 ByDrug, 2022-09-15 ↩

26. "18个月离职魔咒"再现，艾力斯总经理牟艳萍辞职 — 新浪财经, 2022-09-15 ↩↩

27. 伏美替尼2025年"卖爆了"，艾力斯却陷入焦虑 — 新浪财经, 2026-04-24 ↩↩↩↩↩↩↩↩↩↩

28. 艾力斯2025年财报透视：单品独撑52亿营收 后续接棒乏力 — 新浪财经, 2026-04-22 ↩↩↩↩↩↩

29. 上海艾力斯医药科技股份有限公司关于收到仲裁通知的公告 — 上海证券报, 2024-07-10 ↩

30. 上海艾力斯医药科技股份有限公司2025年年度报告 — 上海证券交易所, 2026-04-23 ↩↩↩

31. 翰森制药2025业绩：总收入超150亿元，创新产品收入占比超82% — 东方财富网, 2026-03-30 ↩↩↩↩

32. 国产三代EGFR-TKI竞争白热化，新药陆续报产！贝达药业、圣和药业、艾森医药 — 摩熵医药 ↩↩

33. 艾力斯投资者关系活动记录表（2026年4月23日） — 东方财富网, 2026-04-28 ↩↩↩↩↩↩↩↩↩↩↩↩↩↩↩↩↩↩

34. 伏美替尼再下一城！EGFR 20外显子插入突变肺癌新希望 — 搜狐健康, 2026-02 ↩↩

35. 艾力斯（688578.SH）研究报告 — 开源证券, 2025-04-25 ↩↩

36. 2026 CSCO NSCLC指南重磅更新：EGFR突变围术期治疗四大要点解析 — 腾讯新闻, 2026-04-30 ↩

37. 第十一批国采最终中选结果公布！55种常用药纳入 — 摩熵医药 ↩

38. 《国家基本药物目录(2026年版)》发布，奥希替尼等39个抗肿瘤药物纳入目录 — 新华网, 2026-07-10 ↩

39. 艾力斯(688578.SH)拟授权ArriVent使用公司抗癌药伏美替尼相关海外权益 — 金融界, 2021-06-30 ↩↩

40. ArriVent BioPharma Reports Second Quarter 2026 Financial Results — BioSpace, 2026 ↩↩↩↩

41. 超10亿美元！翰森制药阿美替尼出海 — 药时代, 2025-12-17 ↩

42. 基石药业对外战略合作再下一城 携手艾力斯共同开发中国市场 — 中国证券网, 2023-11-09 ↩

43. 基石药业与艾力斯签订RET抑制剂普吉华®（普拉替尼胶囊）在中国大陆独家商业化推广协议 — 中国医药创新促进会, 2023-11-08 ↩

44. 加科思向艾力斯授权KRAS G12C抑制剂戈来雷塞和SHP2抑制剂JAB-3312中国权益 — 加科思药业, 2024-08-30 ↩

45. 喜讯｜艾力斯获得加科思KRAS G12C抑制剂戈来雷塞和SHP2抑制剂大中华区权益 — 艾力斯, 2024-08-30 ↩

46. Jacobio's KRAS G12C Inhibitor Glecirasib Approved by NMPA for Advanced NSCLC — Jacobio Pharma, 2025-05-22 ↩

47. 艾力斯医药获得ArriVent潜在全球首创ADC权益 — 每日经济新闻, 2026-08-13 ↩↩↩

48. 艾力斯引进潜在全球首创ADC进军妇科肿瘤领域 — 聚焦大分子, 2026-08-19 ↩

49. 艾力斯获得注射用AST2169脂质体药物临床试验批准通知书 — 腾讯新闻, 2024-03-13 ↩

50. Shanghai Allist Pharmaceuticals Co., Ltd. — Drug pipelines, Patents, Clinical trials — Synapse ↩

51. Shanghai Allist Pharmaceuticals Co., Ltd. Official Investor Relations Portal — Allist ↩

52. 艾力斯"爆款神话"：靠一款肺癌药净赚10亿，员工将人均套现千万 — 36氪, 2025 ↩↩

53. AstraZeneca PLC Form 20-F for the year ended 31 December 2025 — US Securities and Exchange Commission, 2026 ↩